vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and CENTRUS ENERGY CORP (LEU). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $146.2M, roughly 1.2× CENTRUS ENERGY CORP). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -3.6%). Over the past eight quarters, CENTRUS ENERGY CORP's revenue compounded faster (82.9% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Centrus Energy Corp. is an American company that supplies nuclear fuel for use in nuclear power plants and works to develop and deploy centrifuge technology to produce enriched uranium for commercial and government uses, including for national security.

ESPR vs LEU — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.2× larger
ESPR
$168.4M
$146.2M
LEU
Growing faster (revenue YoY)
ESPR
ESPR
+147.3% gap
ESPR
143.7%
-3.6%
LEU
Faster 2-yr revenue CAGR
LEU
LEU
Annualised
LEU
82.9%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
LEU
LEU
Revenue
$168.4M
$146.2M
Net Profit
Gross Margin
23.9%
Operating Margin
50.6%
8.8%
Net Margin
Revenue YoY
143.7%
-3.6%
Net Profit YoY
EPS (diluted)
$0.32
$0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
LEU
LEU
Q4 25
$168.4M
$146.2M
Q3 25
$87.3M
$74.9M
Q2 25
$82.4M
$154.5M
Q1 25
$65.0M
$73.1M
Q4 24
$69.1M
$151.6M
Q3 24
$51.6M
$57.7M
Q2 24
$73.8M
$189.0M
Q1 24
$137.7M
$43.7M
Net Profit
ESPR
ESPR
LEU
LEU
Q4 25
Q3 25
$-31.3M
$3.9M
Q2 25
$-12.7M
$28.9M
Q1 25
$-40.5M
$27.2M
Q4 24
Q3 24
$-29.5M
$-5.0M
Q2 24
$-61.9M
$30.6M
Q1 24
$61.0M
$-6.1M
Gross Margin
ESPR
ESPR
LEU
LEU
Q4 25
23.9%
Q3 25
-5.7%
Q2 25
34.9%
Q1 25
45.0%
Q4 24
40.8%
Q3 24
15.4%
Q2 24
19.3%
Q1 24
9.8%
Operating Margin
ESPR
ESPR
LEU
LEU
Q4 25
50.6%
8.8%
Q3 25
-11.4%
-22.2%
Q2 25
8.6%
21.7%
Q1 25
-34.0%
28.0%
Q4 24
-6.4%
29.7%
Q3 24
-31.0%
-13.2%
Q2 24
3.5%
11.2%
Q1 24
52.5%
-24.3%
Net Margin
ESPR
ESPR
LEU
LEU
Q4 25
Q3 25
-35.9%
5.2%
Q2 25
-15.4%
18.7%
Q1 25
-62.2%
37.2%
Q4 24
Q3 24
-57.2%
-8.7%
Q2 24
-83.9%
16.2%
Q1 24
44.3%
-14.0%
EPS (diluted)
ESPR
ESPR
LEU
LEU
Q4 25
$0.32
$0.52
Q3 25
$-0.16
$0.19
Q2 25
$-0.06
$1.59
Q1 25
$-0.21
$1.60
Q4 24
$-0.14
$3.26
Q3 24
$-0.15
$-0.30
Q2 24
$-0.33
$1.89
Q1 24
$0.34
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
LEU
LEU
Cash + ST InvestmentsLiquidity on hand
$167.9M
$2.0B
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$-302.0M
$765.1M
Total Assets
$465.9M
$2.4B
Debt / EquityLower = less leverage
1.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
LEU
LEU
Q4 25
$167.9M
$2.0B
Q3 25
$92.4M
$1.6B
Q2 25
$86.1M
$833.0M
Q1 25
$114.6M
$653.0M
Q4 24
$144.8M
$671.4M
Q3 24
$144.7M
$194.3M
Q2 24
$189.3M
$227.0M
Q1 24
$226.6M
$209.3M
Total Debt
ESPR
ESPR
LEU
LEU
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$390.0M
Q1 25
$389.5M
Q4 24
$472.5M
Q3 24
$83.5M
Q2 24
$86.5M
Q1 24
$86.5M
Stockholders' Equity
ESPR
ESPR
LEU
LEU
Q4 25
$-302.0M
$765.1M
Q3 25
$-451.4M
$363.1M
Q2 25
$-433.5M
$359.1M
Q1 25
$-426.2M
$213.9M
Q4 24
$-388.7M
$161.4M
Q3 24
$-370.2M
$76.4M
Q2 24
$-344.2M
$76.6M
Q1 24
$-294.3M
$33.8M
Total Assets
ESPR
ESPR
LEU
LEU
Q4 25
$465.9M
$2.4B
Q3 25
$364.0M
$2.2B
Q2 25
$347.1M
$1.3B
Q1 25
$324.0M
$1.3B
Q4 24
$343.8M
$1.1B
Q3 24
$314.1M
$591.0M
Q2 24
$352.3M
$668.2M
Q1 24
$373.1M
$750.0M
Debt / Equity
ESPR
ESPR
LEU
LEU
Q4 25
1.54×
Q3 25
3.23×
Q2 25
1.09×
Q1 25
1.82×
Q4 24
2.93×
Q3 24
1.09×
Q2 24
1.13×
Q1 24
2.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
LEU
LEU
Operating Cash FlowLast quarter
$45.2M
$-48.4M
Free Cash FlowOCF − Capex
$-58.0M
FCF MarginFCF / Revenue
-39.7%
Capex IntensityCapex / Revenue
0.0%
6.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$31.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
LEU
LEU
Q4 25
$45.2M
$-48.4M
Q3 25
$-4.3M
$10.1M
Q2 25
$-31.4M
$52.8M
Q1 25
$-22.6M
$36.5M
Q4 24
$-35.0M
$57.9M
Q3 24
$-35.3M
$-33.2M
Q2 24
$-7.2M
$7.0M
Q1 24
$53.8M
$5.3M
Free Cash Flow
ESPR
ESPR
LEU
LEU
Q4 25
$-58.0M
Q3 25
$5.7M
Q2 25
$49.2M
Q1 25
$34.4M
Q4 24
$57.2M
Q3 24
$-35.5M
$-34.2M
Q2 24
$-7.3M
$6.1M
Q1 24
$53.8M
$3.8M
FCF Margin
ESPR
ESPR
LEU
LEU
Q4 25
-39.7%
Q3 25
7.6%
Q2 25
31.8%
Q1 25
47.1%
Q4 24
37.7%
Q3 24
-68.7%
-59.3%
Q2 24
-9.9%
3.2%
Q1 24
39.0%
8.7%
Capex Intensity
ESPR
ESPR
LEU
LEU
Q4 25
0.0%
6.6%
Q3 25
0.0%
5.9%
Q2 25
0.0%
2.3%
Q1 25
0.0%
2.9%
Q4 24
0.0%
0.5%
Q3 24
0.3%
1.7%
Q2 24
0.1%
0.5%
Q1 24
0.1%
3.4%
Cash Conversion
ESPR
ESPR
LEU
LEU
Q4 25
Q3 25
2.59×
Q2 25
1.83×
Q1 25
1.34×
Q4 24
Q3 24
Q2 24
0.23×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

LEU
LEU

Separative Work Units$111.0M76%
Services$21.8M15%
Other$13.4M9%

Related Comparisons